Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Profit Margin: 20.88%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
VRTX Profit Margin Rankings
| Overall | 89th percentile | 440 of 4396 |
| Sector | 92nd percentile | 36 of 470 in Healthcare |
| Industry | 87th percentile | 16 of 132 in Biotechnology |
VRTX Profit Margin Range, Past 5 Years
| Minimum | -898.5% | Jun 2009 |
| Maximum | 33.54% | Sep 2011 |
| Average | -371.0% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these VRTX related companies
VRTX News
$VRTX 01/06/12 12:25 SHRT@ 62.09015 STP@ 64.68113 1stTRGT@ 47.03779 L50 H60.36
about 2 hours ago by yodarbel
about 2 hours ago by yodarbel
Still think $VRTX goes but it sure is being controlled and manipulated. Think it can challenge yesterday's highs if it can get going.
about 19 hours ago by prostocktrader
about 19 hours ago by prostocktrader
$VRTX hi- sticking with 42 target- don't like what happend- see the coil but coils can go either way
about 19 hours ago by crackheadtrader
about 19 hours ago by crackheadtrader
Sure looks like $VRTX still wants to go, big time coiling around the 60+- zone.
about 20 hours ago by prostocktrader
about 20 hours ago by prostocktrader
Jumping back in here on $VRTX (60.22), tight coiliing pattern on 10-minute. Stops below 59.80.
about 21 hours ago by prostocktrader
about 21 hours ago by prostocktrader
$VRTX the whole market is crashing , but this junk even with terrible news is being held up
about 21 hours ago by trendpicker
about 21 hours ago by trendpicker
While it appeared $VRTX wanted to roll over, if it takes out HOD now it would be explosive. Still watching this one.
about 21 hours ago by prostocktrader
about 21 hours ago by prostocktrader
Per earlier comment, closed out $VRTX for very small loss. Sure looks like it wants to roll on over.
about 21 hours ago by prostocktrader
about 21 hours ago by prostocktrader
I've sold $VRTX right after the big jump and I won't buy above $40. I'll wait for $36 again, while I'm holding $AMRN, $DNDN & $OREX :-)
about a day ago by mitrado
about a day ago by mitrado
@trendpicker @ianestepan $VRTX it's being pumped so people can sell out! First phase 2 trial information wrong ,now FDA letter on Incivek!!
about a day ago by BiopharmaPro
about a day ago by BiopharmaPro
Monsanto, Vertex Pharmaceuticals Incorporated Among Stocks Up on High Volume Wednesday
May 30, 4:32PM Fox Business
May 30, 4:32PM Fox Business
Unusual 11 Mid-Day Movers 05/29: (BTFG) (LCRY) (IBI) Higher; (HMPR) (MY) (XG) Lower
May 29, 1:45PM Street Insider
May 29, 1:45PM Street Insider
Vertex Pharmaceuticals Incorporated, Tractor Supply Company Among Stocks Down on Above-average Volume Tuesday
May 29, 12:32PM Fox Business
May 29, 12:32PM Fox Business
Morning Movers 05/29: (BTFG) (LCRY) (IBI) (CNTF) Higher; (VRTX) Lower
May 29, 10:53AM Street Insider
May 29, 10:53AM Street Insider
Needham & Company Maintains Bullish Stance on Vertex (VRTX) Despite Weaker Data
May 29, 10:35AM Street Insider
May 29, 10:35AM Street Insider
Wells Fargo Maintains an 'Outperform' on Vertex (VRTX); Data Not Quite As Strong, But Combo Still Clearly Active
May 29, 9:22AM Street Insider
May 29, 9:22AM Street Insider
Vertex (VRTX) Slammed After Correcting Lower Cystic Fibrosis Trial Data
May 29, 7:42AM Street Insider
May 29, 7:42AM Street Insider
Vertex Pharma (VRTX) Says Lung Function Improvement from VX-809 Phase 2 Was Overstated in Last Release
May 29, 7:02AM Street Insider
May 29, 7:02AM Street Insider
Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
May 25, 7:53AM Street Insider
May 25, 7:53AM Street Insider
U.S. Suggests All Baby Boomers Should Get Tested for Hepatitis C
May 18, 4:24PM The Wall Street Journal
May 18, 4:24PM The Wall Street Journal
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VRTX | 60.04 | -0.14 | -0.23% | 12.63B |
| VRTS | 70.88 | +0.51 | +0.72% | 545.78M |
| VRTB | 1.260 | -0.00 | -0.01% | 16.56M |
| VRTA | 1.10 | -0.04 | -3.51% | 6.974M |
| VRSN | 38.23 | -0.39 | -1.01% | 6.098B |
| VRSK | 47.90 | +0.01 | +0.02% | 7.893B |
| VRS | 1.15 | +0.04 | +3.60% | 60.48M |
| VRNT | 28.72 | -0.32 | -1.10% | 1.116B |
| VRNM | 3.58 | +0.16 | +4.68% | 45.14M |
| VRNG | 3.79 | +0.29 | +8.29% | 23.61M |